摘要:
The present invention is directed to substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds of formula (I): and forms thereof and their synthesis and use as protein kinase inhibitors and interactions thereof.
摘要:
The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. In addition, the present invention relates to methods treating disorders related to matrix metalloproteases. More particularly, the compounds of the present invention are useful for treating stroke.
摘要:
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
摘要:
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3-R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(═O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.
摘要翻译:提供了治疗或预防与NMDA受体活性相关的病症的化合物,药物组合物和方法,包括神经性疼痛,中风,创伤性脑损伤,癫痫以及相关的神经系统事件或神经变性。 化合物为通式I,或其药学上可接受的盐,酯,前药或衍生物:其中:(L)k-Ar1为取代或未取代的单或双环芳基或杂芳基; W是键,烷基或烯基; X是键,NR 1或O,并且每个R 1和R 2独立地是H,烷基,烯基或芳烷基,或者R 1和R 2一起形成5-8元环; R 3 -R 6选自某些具体取代基或羰基; Y是键,O,S,SO,SO 2,CH 2,NH,N(烷基)或NHC(= O); 并且Z是OH,NR 6 R 7,NR 8 SO 2(烷基),NR 8 C(O)NR 6 R 7,NR 8 C(O)O(烷基),NR 8 - 二氢噻唑或NR 8 - 二氢咪唑,或其中Z可与Ar 2融合形成选定的杂环。
摘要:
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.
摘要:
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers
摘要:
A method for packaging fresh meat in a substantially oxygen-free atmosphere, whereby the packaging provides for a prolonged shelf life of the packaged meat products so that the meat will bloom to a desired red color when the packaging is opened. The packaging includes a packing tray which is sized for receiving a piece of fresh meat of predetermined cut. The tray is overwrapped with a web of clear plastic wrapping material. The overwrapped tray is ventilated to ensure gas communication between enclosed regions of the overwrapped tray and the outside ambient without blockage due to run off juices from the meat product or shifting of the meat product within the tray during transport. A number of similarly ventilated overwrapped trays are then placed within an outer barrier bag which is first evacuated of normal atmosphere and then flushed with a preservation-enhancing gas. The outer barrier bag is then sealed. Upon opening of the outer barrier bag, exposure to oxygen causes the packaged meat products to bloom to a desired fiery red color. Upon removal from the outer barrier bag, the ventilated overwrapped trays are ready for retail case-ready display without the need for repackaging or cosmetic repair.
摘要:
A package for packaging fresh meat in a substantially oxygen-free atmosphere, whereby the packaging provides for a prolonged shelf life of the packaged meat products so that the meat will bloom to a desired red color when the packaging is opened. The packaging includes a packing tray which is sized for receiving a piece of fresh meat of predetermined cut. The tray is overwrapped with a web of clear plastic wrapping material. The overwrapped tray is ventilated to ensure gas communication between enclosed regions of the overwrapped tray and the outside ambient without blockage due to run off juices from the meat product or shifting of the meat product within the tray during transport. A number of similarly ventilated overwrapped trays are then placed within an outer barrier bag which is first evacuated of normal atmosphere and then flushed with a preservation-enhancing gas. The outer barrier bag is then sealed. Upon opening of the outer barrier bag, exposure to oxygen causes the packaged meat products to bloom to a desired fiery red color. Upon removal from the outer barrier bag, the ventilated overwrapped trays are ready for retail case-ready display without the need for repackaging or cosmetic repair.
摘要:
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3−-R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(═O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.
摘要翻译:提供了治疗或预防与NMDA受体活性相关的病症的化合物,药物组合物和方法,包括神经性疼痛,中风,创伤性脑损伤,癫痫以及相关的神经系统事件或神经变性。 化合物为通式I,或其药学上可接受的盐,酯,前药或衍生物:其中:(L)k-Ar1为取代或未取代的单或双环芳基或杂芳基; W是键,烷基或烯基; X是键,NR 1或O,并且每个R 1和R 2独立地是H,烷基,烯基或芳烷基,或者R 1和R 2一起形成5-8元环; R 3 -R 6选自某些具体取代基或羰基; Y是键,O,S,SO,SO 2,CH 2,NH,N(烷基)或NHC(= O); 并且Z是OH,NR 6 R 7,NR 8 SO 2(烷基),NR 8 C(O)NR 6 R 7,NR 8 C(O)O(烷基),NR 8 - 二氢噻唑或NR 8 - 二氢咪唑,或其中Z可与Ar 2融合形成选定的杂环。
摘要:
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring; R3−R6 are selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO2, CH2, NH, N(alkyl), or NHC(═O); and Z is OH, NR6R7, NR8SO2(alkyl), NR8C(O)NR6R7, NR8C(O)O(alkyl), NR8-dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.
摘要翻译:提供了治疗或预防与NMDA受体活性相关的病症的化合物,药物组合物和方法,包括神经性疼痛,中风,创伤性脑损伤,癫痫以及相关的神经系统事件或神经变性。 化合物为通式I,或其药学上可接受的盐,酯,前药或衍生物:其中:(L)k-Ar1为取代或未取代的单或双环芳基或杂芳基; W是键,烷基或烯基; X是键,NR 1或O,并且每个R 1和R 2独立地是H,烷基,烯基或芳烷基,或者R 1和R 2一起形成5-8元环; R 3 -R 6选自某些具体取代基或羰基; Y是键,O,S,SO,SO 2,CH 2,NH,N(烷基)或NHC(= O); 并且Z是OH,NR 6 R 7,NR 8 SO 2(烷基),NR 8 C(O)NR 6 R 7,NR 8 C(O)O(烷基),NR 8 - 二氢噻唑或NR 8 - 二氢咪唑,或其中Z可与Ar 2融合形成选定的杂环。